http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009530285-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2007-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2009530285-A |
| titleOfInvention | Combination therapy with EGFR kinase inhibitors and agents that sensitize tumor cells to the effects of EGFR kinase inhibitors |
| abstract | The invention relates to the manufacture of a medicament intended for the treatment of NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in combination with an EGFR kinase inhibitor, characterized in that an mTOR inhibitor is used. Wherein the inhibitor is intended for either simultaneous or sequential administration, with or without other anti-cancer agents or additional agents such as radiation therapy, or in combination with or treatment . Another object of the present invention is to treat a tumor or tumor metastasis in a patient by using in combination with an EGFR kinase inhibitor, wherein an mTOR inhibitor that binds to and directly inhibits both mTORC1 and nTORC2 kinases is used. Wherein the inhibitor is intended for either simultaneous or sequential administration, with or without other anti-cancer agents or with additional agents such as radiotherapy or in combination with treatment. A method is also provided. The present invention also provides a pharmaceutical composition comprising, in a pharmaceutically acceptable carrier, an EGFR kinase inhibitor and an mTOR inhibitor that binds and directly inhibits both mTORC1 and mTORC2 kinase. A desirable embodiment of an EGRF kinase inhibitor that can be used to practice the methods of the invention is the compound erlotinib HC1 (also known as TARCEVA®). |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015532287-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017538677-A |
| priorityDate | 2006-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1823.